Union for International Cancer Control (UICC)

Spotlight on
Healthcare working using new technology
Read more
cancer treatment
Read more
Middle-eastern woman with headscarf and lab coat checking a screen, with a man in lab coat standing just behind her
Read more
Close up of radio scan in hands of professional doctors detecting problems
Read more
Black woman in lab coat running analyses
Read more
Close up of a hand of a hospital patient receiving IV antibiotics
Read more

Leading global action on cancer

Members

Partners

Countries

UICC provides learning and development opportunities for members. Member organisations have privileged access to UICC events and voting rights as part of the General Assembly.

UICC fosters a learning culture across the cancer community, encourages collaboration and offers a range of knowledge sharing opportunities.

Uniting cancer professionals and policy makers in premier events like the World Cancer Congress and World Cancer Leaders’ Summit is an essential part of UICC’s work. UICC also leads on the global World Cancer Day campaign. 

Prof. Jeff Dunn, President of UICC 2022-2024, speaking at the World Cancer Leaders' Summit 2023 in Long Beach, CA, United States in November 2023.

Political will and a national strategy that prioritises targeted investments in cancer control as well as action at the international level can reduce the global cancer burden. 

Anil D'Cruz, now UICC's Immediate-Past-President launching the ATOM Coalition in May 2022

UICC has created several new organisations and initiatives to address long-term public health challenges and unmet needs.

Woman examines patient in front of mammography machine

While UICC works on all aspects of cancer control covering all cancer types, the organisation pays special attention to a number of key thematic areas.

Explore more
Caregiver talking to a woman who has just received cancer treatment

What is cancer control?

Cancer control aims to reduce the incidence, morbidity and mortality of cancer and to improve the quality of life of cancer patients in a defined population, through the systematic implementation of evidence-based interventions for prevention, early detection, diagnosis, treatment, and palliative care.

Explore more

News and updates

UICC awards 38 Technical Fellowships, providing invaluable training opportunities for cancer professionals from around the world

Headshot of a young Black doctor
Read more

Strengthening access to oncology medicines in Mongolia

Participants of the ATOM Coalition Mongolia workshop - November 2024, visiting the the Health Minister of Mongolia
Read more

The misleading and industry-friendly narrative of Sweden's 'smoke-free' status

Open box of smokeless tobacco snus
Read more
View all news and updates

Featured resources

wcc24_summary_report_a4_fa_single_pages.pdf
Author(s):
Union for International Cancer Control (UICC)
Download (
5.17 MB
)
Breast cancer advocacy handbook
Author(s):
Union for International Cancer Control (UICC)
Download (
2.47 MB
)
Integrated approaches for women’s cancers: Opportunities to advance health for women
Author(s):
Union for International Cancer Control (UICC)
Download (
5.73 MB
)
View all resources

Upcoming events

Stay up to date with all the information related to our contributions and to the international events in the field.

See all upcoming events

Suggest an event

04 February2025
Geneva , Switzerland
Organiser(s):
Union for International Cancer Control (UICC)
See details

Our
partners

Over 50 partners drive long-term and measurable changes in cancer control for the benefit of the global cancer community.

View all partners

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.  

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

Founded in 1951 to support cancer research, the Swedish Cancer Society is an independent non-profit organization with the vision of finding cures for cancer. The overall aim of the Society is to achieve a higher survival rate and a reduction in the incidence of cancer. Their main task is to raise and distribute money for cancer research. As one of the largest financiers of cancer research in Sweden, the Swedish Cancer Society essentially acts as a national research council. Thanks to the organization’s extensive knowledge about cancer, the Swedish Cancer Society is also active in areas such as public opinion and spreading knowledge about cancer, as well as results of cancer research.

The Dutch Cancer Society is a nation-wide organization for cancer control in the Netherlands. The society was funded in 1949 by Queen Wilhelmina. Her granddaughter, Her Royal Highness Princess Beatrix, is the current patron. The Dutch Cancer Society’s ideal world is one in which nobody dies from cancer ever again. We want fewer people to get cancer, more people to cure, and patients to have a better quality of life, during and after the disease. That’s why we fund and facilitate scientific research, influence policy, and share our knowledge about cancer and its treatment. To make this possible, we raise funds and establish links with other parties involved in cancer control, both here in the Netherlands and elsewhere. The Dutch Cancer Society is entirely dependent on community involvement and donations. Over 100.000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We can rely on nearly 1.500 local committees that organize fundraising activities e.g. our annual door-to-door campaign to raise funds for the fight against cancer. The Dutch Cancer Society is supported by over 1 million donors. The Dutch Cancer Society’s office is located in Amsterdam; our professional staff amounts to 198 staff members.

N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. Recommended by 90,000 dermatologists worldwide*, La Roche-Posay was created by a pharmacist in 1975. The brand is today present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin.  The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer specifically. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare. Since 2019, the Fondation La Roche-Posay is also committed to improving the life of children with cancer and their families. In 2020, the brand went a step further in its commitment to protect the planet. Besides launching the first eco-designed tubes integrating cardboard, the brand announced a long-term plan to reduce its use of virgin plastic by 70% in 2025.

For additional information about La Roche-Posay, visit www.laroche-posay.com.

*source: survey on the dermocosmetic market carried out by iqvia and other partners (ipsos, tns) between september 2017 and august 2018 among dermatologists in 62 countries.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

61 days

until

World Cancer Day 2025

Learn more

348 days

until

World Cancer Leaders' Summit 2025

Learn more

Are you interested in joining a dynamic network of over 1,150 members?

Become a member

Would you like to support the work of UICC and the cancer community?

Become a partner

Are you organising a cancer-related event and would like to feature it in our events section?

Submit an event